Form 8-K · Current report
Amgen 8-K, filed Nov 3, 2026
- Filed
- CIK
- 0000318154
- Accession no.
- 0000318154-26-000153
Summary
Amgen reported third-quarter 2026 total revenues rose 8% to $10.4 billion and GAAP EPS rose 19% to $7.08, while non-GAAP EPS increased 14% to $6.45. CEO Robert A. Bradway said the strength of the commercial portfolio, clinical advances, and late-stage pipeline reinforced confidence in durable long-term growth.
Key points
- Total revenues increased 8% to $10.4 billion in Q3 2026, with product sales up 8% on volume growth.
- GAAP EPS rose 19% to $7.08 and non-GAAP EPS rose 14% to $6.45.
- Free cash flow was $3.7 billion, down from $4.2 billion a year earlier.
- Repatha sales rose 37% to $1.085 billion, UPLIZNA sales rose 191% to $451 million, and Prolia sales fell 45% to $632 million after biosimilar launches.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. Third Quarter 2026 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On November 3, 2026, the Company issued a press release announcing its unaudited results of operations for the three and nine months ended September 30, 2026, and its unaudited financial position as of September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.